Dan­ish biotech seek­ing niche vac­cine edge against Pfiz­er snags €72M for piv­otal study

A biotech 12 years in the mak­ing has se­cured its largest fi­nanc­ing yet, and it has am­bi­tious plans for what the chief ex­ec­u­tive called a “David vs. Go­liath” ven­ture.

Min­er­vaX, based out of Copen­hagen, put out word bright and ear­ly Thurs­day that it se­cured €72 mil­lion in new fund­ing via both eq­ui­ty fi­nanc­ing and a loan. This is the biotech’s biggest fi­nanc­ing since 2020, when Sanofi and No­vo, among oth­ers, in­vest­ed $57 mil­lion (€47.4 mil­lion at the time) in Se­ries B fund­ing. €50 mil­lion of the €72 mil­lion is com­ing through a loan from the Eu­ro­pean In­vest­ment Bank.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER